Press Releases

Proceeds to advance clinical development of WU-NK-101 for relapsed/refractory AML, and initiate studies in solid tumor indications. Oversubscribed Series B co-led by Abingworth and Tybourne …

Biotech Executive and former Vice President of Research & Development at Takeda Pharmaceuticals brings notable expertise in cell therapies and strategic business development to the …

ST. LOUIS, MO, March 8, 2021 /PRNewswire/ – Wugen Inc., a clinical-stage biotechnology company developing novel universal natural killer (NK) and T-cell therapies for the …

ST. LOUIS, MO, March 2, 2021 /PRNewswire/ – Wugen Inc., a biotechnology company developing novel, universal allogeneic cell therapy platforms, today announced that it has …

ST. LOUIS, March 1, 2021 – Wugen Inc., a biotechnology company developing novel, universal allogeneic off-the-shelf cell therapies, today announced the appointment of the company’s …

ST. LOUIS, MO, February 22, 2021 /PRNewswire/ – Wugen Inc., a biotechnology company developing novel, universal allogeneic cellular therapies, today announced that it has entered …

ST. LOUIS, February 22, 2021 – Wugen Inc., a biotechnology company developing novel, universal allogeneic off-the-shelf cell therapies, today announced the appointment of Jan Davidson …

ST. LOUIS, Nov. 19, 2020 /PRNewswire/ — Wugen Inc., a biotechnology company developing a novel, universal allogeneic CAR-T therapy platform, today announced the appointment of Ryan Sullivan, Ph.D., as …

ST. LOUIS, April 30, 2019 /PRNewswire/ — Wugen Inc., a biotechnology company developing a novel, universal allogeneic CAR-T therapy platform, today announced the appointment of Mark Lewis, Ph.D., …

ST. LOUIS, March 26, 2019 /PRNewswire/ — WUGEN Inc., a biotechnology company developing a novel, universal allogeneic CAR-T therapy platform, today announced the appointment of Ayman Kabakibi, Ph.D., as …

ST. LOUIS, Feb. 20, 2019 /PRNewswire/ — WUGEN Inc., a biotechnology company developing a novel, universal allogeneic CAR-T therapy platform, today announced data presentations at the 2019 Transplantation …

ST. LOUIS, Dec. 3, 2018 /PRNewswire/ — WUGEN Inc., a biotechnology company developing a novel universal allogeneic CAR-T therapy platform, today announced updated preclinical data that validates …

ST. LOUIS, Nov. 13, 2018 /PRNewswire/ —  WUGEN Inc., a biotechnology company developing a novel universal allogeneic CAR-T therapy platform, today announced that it has entered into …

ST. LOUIS, Nov. 1, 2018  /PRNewswire/ — WUGEN Inc., a biotechnology company developing a novel universal allogeneic CAR-T therapy platform, today announced that abstracts showcasing the WUGEN …

Latest News

Proceeds to advance clinical development of WU-NK-101 for relapsed/refractory AML, and initiate studies in solid …

Source: SITEMAN Cancer Center, Julia Evangelou Strait, June 2021.

Next in our story